Mr. Brent Willis reports

VOYAGEUR PHARMACEUTICALS LTD. ADVANCES WITH ENVIRONMENTAL FIELD WORK AT FRANCES CREEK PROJECT SITE FOR NOTICE OF WORK & QUARRY PERMITTING

Voyageur Pharmaceuticals Ltd. has completed environmental and geotechnical fieldwork at its Frances Creek project site. This milestone represents a significant achievement for the corporation and its 100-per-cent-owned subsidiary, Voyageur Industrial Minerals Ltd., as it fulfills both the exploration notice of work for barite sampling from the surface vein and paves the way for future quarry permitting.

Undertaken in collaboration with Vast Resource Solutions, a firm based in Cranbrook, B.C., the detailed site assessment encompassed a comprehensive evaluation of existing baseline conditions within and surrounding the site. It also involved meticulous collection of soil and rock samples, along with a thorough review of the current and potential site access road.

The data, samples and road assessment gathered during this process will serve as crucial inputs for various planning aspects, including site soil handling and reclamation, invasive weed management practices, acid rock drainage/metal leaching potential, process area planning, and safe access road options.

Voyageur firmly upholds its commitment to environmental stewardship and sustainability, and this is evident in the work conducted at Frances Creek. All activities have been carried out in strict compliance with rigorous environmental standards. As part of the company's dedication to transparency and regulatory adherence, the findings and outcomes of the fieldwork will be promptly submitted to the BC Ministry of Mines.

About Voyageur Pharmaceuticals Ltd.

Voyageur is a Canadian public company listed on the TSX Venture Exchange under the trading symbol VM. Voyageur is focused on the development of barium and iodine active pharmaceutical ingredients (API) and high-performance cost-effective imaging contrast agents for the medical imaging marketplace. Voyageur's goal is to fully integrate the barium and iodine contrast market by producing its own minerals of barium and iodine.

The business plan is to initially generate cash flow from operations using third party GMP (Good Manufacturing Practice) pharmaceutical manufacturers in Canada and validate the products for regulatory agencies globally. Then transitioning into a high margin domestic manufacturer of radiology drugs. Voyageur has plans to build carbon neutral infrastructure to become 100 per cent self-sufficient across all manufacturing activities. Voyageur owns a 100-per-cent interest in three barium sulphate (barite) projects, including the Frances Creek property, suitable in grade for the pharmaceutical marketplace, with additional interests in a high-grade iodine, lithium and bromine brine project located in Utah, United States. Voyageur is moving forward with its business plan of becoming the only fully integrated carbon neutral company in the radiology contrast media drug market, by controlling all primary input costs under the motto of "From the earth to the bottle."

We seek Safe Harbor.